Skip to content

Effects of seaweed on blood glucose

Potential of seaweed in reducing blood glucose of obese type 2 diabetes patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON20760
Enrollment
60
Registered
2019-08-30
Start date
2019-05-13
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes type 2

Interventions

Patients will receive either 5 gram of Sargassum fusiforme (Sargassum), 5 gram of Fucus vesiculosus (Fucus) or placebo (0.5 gram Nori) during 5 weeks (week 2-6).

Sponsors

Erasmus Medical Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Patients with T2DM and BMI>25 - All adults; age = 18 years - Diabetes based on criteria of ADA

Exclusion criteria

Exclusion criteria: - Type 1 or monogenetic forms of diabetes. - Thyroid disease - Pregnancy - Usage of corticosteroids - Usage of blood anti-coagulants - History of heart failure or recent myocardial infarction within 3 months - Transplantation - Allergy for shellfish

Design outcomes

Primary

MeasureTime frame
Difference between the mean blood glucose levels measured during the first week of usual diet and during week 2 to 6 when daily seaweed is consumed.

Secondary

MeasureTime frame
differences between week 1 and week 6 in terms of body weight (kg); HbA1c and total daily insulin use, and fasting blood glucose levels (Mmol/L) in addition to the continuously monitored glucose levels. Levels of total cholesterol, LDL-cholesterol, HDL-cholesterol, lipoprotein (a) (g/L), apoB100/48 (Mmol/L) and triglycerides (Mmol/L) (measured using routine laboratory analysis) will be analyzed, and pulse wave velocity and blood pressure (mmHg) and cytokines.

Contacts

Public ContactKirsten Berk

Erasmus MC

k.berk@erasmusmc.nl0617512121

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)